Rubicon Research Share Price Today

General Atlantic sells 8.45% stake in Rubicon Research

General Atlantic sold 1.4 crore shares in Rubicon Research. Promoter stake reduced from 35.79% to 27.34%. Sale occurred via on-market transactions on Aug 25-26. Post-disposal holding remains above 25% threshold.

Rubicon Research AGM passes all 9 resolutions, approves KIA merger

All nine resolutions at Rubicon Research's 27th AGM on August 26, 2026 were passed with requisite majority via remote e-voting and e-voting at the meeting. The scheme to merge wholly owned subsidiary KIA Health Tech Private Limited with Rubicon Research was approved under Section 233 of the Companies Act, 2013, requiring a 90% majority. ESOP 2026 for eligible employees and its extension to subsidiary employees were both passed as special resolutions, with 97.15% and 97.20% votes in favour respectively. Consolidated revenue from operations rose 37% to ₹17,540 million in FY26, while net profit after tax grew to ₹2,467 million from ₹1,344 million in FY25. Shareholders' funds rose to ₹12,888 million as of March 31, 2026, while borrowings fell to ₹2,594 million from ₹3,932 million.

Rubicon Research Q1 profit up 96% to ₹848 crore; acquires US plant

Rubicon Research delivered strong Q1FY27 results with net profit rising 96% YoY to ₹848 million and revenue growing 51% to ₹5.3 billion. The company expanded its EBITDA margin to 24.15% and revised full-year guidance upwards to 23%. Key strategic moves include the acquisition of a US manufacturing facility for USD2.9 million and successful resolution of FDA observations at its Pithampur plant.

Rubicon Research Q1 Results: Unaudited financials filed for June 30 quarter

Rubicon Research Limited filed unaudited Q1FY26 standalone and consolidated results with BSE and NSE on August 15, 2026. Published in Financial Express and Loksatta per SEBI Reg 47. No specific financial metrics disclosed in the notice.

Rubicon Research AGM: ₹1.50 Dividend, KIA Merger on Agenda

Rubicon Research Limited convenes its 27th AGM on August 26, 2026, to approve a ₹1.50 per share dividend and the merger of KIA Health Tech Private Limited. Shareholders will also ratify a new ESOP plan and director remuneration, reflecting the company's post-IPO focus on operational efficiency and talent retention.

Rubicon Research Q1 Results: Earnings call scheduled for Aug 14, 2026

Rubicon Research Limited has announced a Q1FY27 earnings conference call on August 14, 2026, at 6:00 PM IST, to discuss financial results for the quarter ended June 30, 2026. The call will feature senior management including CEO Mr. Parag Sancheti, CFO Mr. Nitin Jajodia, and SVP Mr. Sagar Oak, moderated by Tushar Manudhane of Motilal Oswal Financial Services. Dial-in access is available via primary numbers +91 22 6280 1149 / +91 22 7115 8050, with international toll-free lines for the USA, UK, Singapore, and Hong Kong.